Details for Patent: 7,732,430
✉ Email this page to a colleague
Which drugs does patent 7,732,430 protect, and when does it expire?
Patent 7,732,430 protects NEXTSTELLIS and is included in one NDA.
This patent has ninety-two patent family members in twenty-nine countries.
Summary for Patent: 7,732,430
| Title: | Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception |
| Abstract: | A method of contraception in mammalian females, which method comprises the oral administration of an estrogenic component and a progestogenic component to a female of childbearing capability in an amount effective to inhibit ovulation, wherein the estrogenic component is selected from the group consisting of substances represented by the following formula (1) ##STR00001## in which R.sub.1, R.sub.2, R.sub.3, R.sub.4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R.sub.5, R.sub.6, R.sub.7 is a hydroxyl group; and no more than 3 of R.sub.1, R.sub.2, R.sub.3, R.sub.4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. Another aspect of the invention concerns a pharmaceutical kit comprising oral dosage units that contain the aforementioned estrogenic component and/or a progestogenic component. |
| Inventor(s): | Bunschoten; Evert Johannes (Heesch, NL), Coelingh Bennink; Herman Jan Tijmen (Driebergen, NL), Holinka; Christian Franz (New York, NY) |
| Assignee: | Pantarhei Bioscience B.V. (Zeist, NL) |
| Application Number: | 10/478,365 |
|
Patent Claim Types: see list of patent claims | Composition; Device; Dosage form; |
Drugs Protected by US Patent 7,732,430
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma | NEXTSTELLIS | drospirenone; estetrol | TABLET;ORAL | 214154-001 | Apr 15, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | USE BY FEMALES OF REPRODUCTIVE POTENTIAL TO PREVENT PREGNANCY | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,732,430
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 01201945 | May 23, 2001 | |
| 01201946 | May 23, 2001 | |
| 01201947 | May 23, 2001 | |
| PCT Information | |||
| PCT Filed | May 23, 2002 | PCT Application Number: | PCT/NL02/00331 |
| PCT Publication Date: | November 28, 2002 | PCT Publication Number: | WO02/094279 |
